When evaluating the added therapeutic value of a drug, evidence of greater overall benefit or at least an add-on benefit is increasingly being required. Therefore, cost-effectiveness in addition to clinical efficacy is an important consideration. The efficacy of a drug must be examined on the basis of clinical trials by measuring specific parameters that are affected by the drug (for example blood pressure with antihypertensive treatment).
View Article and Find Full Text PDFExpert Rev Pharmacoecon Outcomes Res
June 2005
More than 2.8% of the population in the USA suffer from chronic heart failure, a condition that primarily afflicts people above the age of 60 years, and results in major expenses for social and health care of affected patients, their caregivers and families. The mainstay of treatment is drug therapy, complemented by comprehensive rehabilitation, invasive procedures, palliative treatment and monitoring.
View Article and Find Full Text PDF